Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for InspireMD (NSPR) over the last 16 years, with Q3 2025 value amounting to $1.3 million.

  • InspireMD's Other Non-Current Assets rose 3303.21% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 3303.21%. This contributed to the annual value of $1.1 million for FY2024, which is 1871.71% up from last year.
  • Per InspireMD's latest filing, its Other Non-Current Assets stood at $1.3 million for Q3 2025, which was up 3303.21% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, InspireMD's Other Non-Current Assets registered a high of $1.3 million during Q3 2025, and its lowest value of $723000.0 during Q1 2021.
  • In the last 5 years, InspireMD's Other Non-Current Assets had a median value of $905000.0 in 2021 and averaged $945105.3.
  • As far as peak fluctuations go, InspireMD's Other Non-Current Assets crashed by 612.02% in 2023, and later skyrocketed by 3303.21% in 2025.
  • Quarter analysis of 5 years shows InspireMD's Other Non-Current Assets stood at $905000.0 in 2021, then dropped by 5.41% to $856000.0 in 2022, then grew by 11.1% to $951000.0 in 2023, then increased by 18.72% to $1.1 million in 2024, then grew by 17.36% to $1.3 million in 2025.
  • Its Other Non-Current Assets stands at $1.3 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.1 million for Q1 2025.